State of New Jersey Common Pension Fund D Grows Stock Holdings in ADMA Biologics Inc $ADMA

Key Points

• The State of New Jersey Common Pension Fund D increased its stake in ADMA Biologics Inc by 22.5% during the first quarter, owning approximately $2.47 million worth of shares.
• Insiders at ADMA Biologics have recently sold a significant amount of shares, with one director selling 10,000 shares for about $213,100, representing a 2.05% decrease in their ownership.
• ADMA Biologics reported a quarterly earnings per share of $0.15, beating analysts' estimates, while quarterly revenue increased by 13.8% year-over-year.

State of New Jersey Common Pension Fund D increased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 22.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 124,646 shares of the biotechnology company's stock after purchasing an additional 22,893 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.05% of ADMA Biologics worth $2,473,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Cetera Investment Advisers boosted its position in shares of ADMA Biologics by 1.3% during the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock worth $1,002,000 after purchasing an additional 670 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ADMA Biologics by 1.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock worth $1,323,000 after purchasing an additional 711 shares during the period. GF Fund Management CO. LTD. boosted its position in shares of ADMA Biologics by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock worth $120,000 after purchasing an additional 1,089 shares during the period. Journey Strategic Wealth LLC boosted its position in shares of ADMA Biologics by 6.6% during the 1st quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock worth $354,000 after purchasing an additional 1,102 shares during the period. Finally, KBC Group NV boosted its position in shares of ADMA Biologics by 11.5% during the 1st quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock worth $223,000 after purchasing an additional 1,154 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ADMA shares. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $27.67.

Insider Transactions at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director directly owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 455,621 shares of company stock valued at $9,461,633. Insiders own 3.50% of the company's stock.

ADMA Biologics Stock Up 0.9%

ADMA stock traded up $0.15 during midday trading on Wednesday, hitting $17.25. The company's stock had a trading volume of 3,740,356 shares, compared to its average volume of 3,351,694. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The firm has a market capitalization of $4.12 billion, a P/E ratio of 20.06 and a beta of 0.38. The firm has a 50-day simple moving average of $17.79 and a 200-day simple moving average of $18.88.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. During the same quarter last year, the company posted $0.13 EPS. The firm's revenue was up 13.8% compared to the same quarter last year. As a group, equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.